



Questions


- 1. To what extent are missing data reported in accordance with current reporting guidance?
- 2. Does the quality of reporting differ between missing data reporting criteria specified by CONSORT vs. those not specified by CONSORT?
- 3. Are journal impact factor and CONSORT endorsement status associated with the quality of missing data reporting?

Method: Systematic review

- P= advanced life-limiting disease
- I = palliative
 C= palliative / usual care / placebo
 O = Patient reported / dependent
- S = RCTs
- Information specialist searched: CENTRAL, OVID Medline, EMBASE (Jan 2009-April 2014)
- Random selection / no language restrictions / double screening, selection, extraction

Method: Reporting criteria

- Proportion of missing data
- Reasons for missing data
- Minimising missing data
- Risk of bias posed by missing data
- 5. Justification of missing data analytical
- Statistical methods to handle missing data
- Impact of missing data on trial findings



Q1. To what extent are missing data reported in accordance with current reporting guidance?

1. Proportion of missing data

Missing data reporting criterion	Proportion of trials reporting the criterion	
Account for all participants who enter the study	69% (75/108)	
Report number of participants not included in the primary outcome analysis	94% (101/108)	
Report number of participants with missing data in each arm in the primary outcome analysis (non- crossover trials)	87% (85/98)	
Report amount of item-level missing data in the primary outcome analysis (if primary outcome was a scale summary)	10% (5/50)	
Report missing data trend over time for primary outcomes measured repeatedly	All time points: 7% (5/69) Some time-points: 48% (33/69)	
Report amount of missing data for secondary	For all: 9% (9/99)	
outcomes if measured	For some: 18% (18/99)	

2. Reason for missing data

Missing data reporting criterion	Proportion of trials reporting the criterion	
Report reason for missing data	71% (66/931)	
Report amount of missing data due to death	65% (60/93)	
Report amount of missing data due to illness/disease progression	46% (43/93)	

² Fifteen trials reported no missing data

For 53% of participants with missing data the reason was described as 'LTFU' or 'withdrawal' only

3. Minimising & 4. Risk of bias

Missing data reporting criterion	Proportion of trials reporting the criterion
Report plans to minimise missing data	27% (29/108)
Report comparison of baseline characteristics of those with observed data	6% (6/93)
Report comparison of baseline characteristics of those with missing data	0%

5. Justification of missing data analytical approach

Missing data reporting criterion	Proportion of trials reporting the criterion	
Report assumed mechanism of missing	3% (3/108)	
data		
Report criteria for missing not at	1% (1/108)	
random (informative missing data)		
Report pattern of missingness	0%	
Compare baseline characteristics of	13% (12/93)	
those with and without missing data		


6. Statistical methods to handle missing data

Missing data reporting criterion	Proportion of trials reporting the criterion	
Report methods used to handle missing data	48% (45/93)	
Report missing data sensitivity analyses	16% (15/93)	
Report any changes to the planned missing data analysis	0%	

7. Impact of missing data on the trial findings

- **46% (43/93)**
- Limitations section
- 13 discussed potential for missing data to bias the treatment effect estimate

Q2. Does the quality of reporting differ between criteria specified by CONSORT vs. those not specified by CONSORT?



Q3. Are journal impact factor and CONSORT endorsement status associated with the quality of missing data reporting?

	Journal impact factor (Median 2.8, 0-56)		CONSORT endorsement status	
Reporting criterion	Odds ratio per JIF doubling	95% CI	Odds ratio	95% CI
Account for all participants*	1.54	1.20, 1.97	2.46	0.73, 8.23
No. of participants not included in the primary outcome analysis*	1.39	1.15, 1.69	1.20	0.31, 4.70
Reasons for MD*	0.88	0.63, 1.23	0.65	0.20, 2.17
Plans to minimise MD	1.16	0.94, 1.42	1.00	0.40, 2.49
Compare baseline characteristics of those with and without MD	1.50	1.20, 1.87	1.11	0.42, 2.92
Methods to handle MD	1.40	1.13, 1.73	2.53	1.08, 5.94
MD sensitivity analyses	1.20	0.81, 1.80	3.48	1.15, 10.50
Impact on findings	1.14	0.93, 1.41	1.85	0.85, 4.04

So what?

- Q1. The reporting of missing data in palliative care trials does not comply fully with current reporting guidance
- Q2. Criteria specified by CONSORT were better reported
- Q3. The odds of reporting the majority of the MD criteria increased as journal impact factor increased and in journals that endorsed the CONSORT statement



- Reads section:

 2. Even the following measures of amount of trinsing data:

 2. Even and noticemer, unables of principates in each arm with mining data (unto level mining data).

 3. For each noticemer, unables of principates in each arm with mining data (unto level mining data).

 5. For exclusives that are called assumatives, amount of fears level mining data, for example the number of participates in each arm with some in more internations; and/or the properties of fears-level mining data.

 6. For expented exclusives, number of participates in each arm with mining data of each time, point.

 7. Excession for mining data in each arm, with except decided that their expensed reasons can be used to realize the uncertainty about the potential under fearing data, although this will not be verifiable using the partially observed data. If terms such as less to follow up or withdrawal are used, the effort.